Navigation Links
ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
Date:8/23/2007

9, Met (O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species. All of the Company's research and development efforts are early, pre-clinical stage and Homspera(TM), as Viprovex(R) and Radilex(TM), has only undergone exploratory studies to evaluate its biological activity in small animals.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(R) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at http://www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expect
'/>"/>

SOURCE ImmuneRegen BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Third Wave responds to Digene patent lawsuit
2. Epic responds to critics of electronic record installation
3. Small Tree Communications awarded $2.85M defense contract
4. Research consortium aims to bring security and defense contracts to Wisconsin
5. MATC student team wins cyber defense contest
6. National Bio and Agro Defense fits Wisconsin
7. Chippewa Valley firms land more defense work
8. Wisconsins failure to attract federal defense dollars crimps tech economy
9. Defense contract helps Plexus gain record profits
10. Chippewa Valley to get $46 million in defense spending
11. Wisconsins untapped defense might: why saving military bases is just a start
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Marrone Bio Innovations (MBI) today announces 2 new ... Hildreth joined MBI as Senior Vice President of ... commercial aspects of the company, including sales, marketing, ... Lam joined MBI as Vice President of Process ... scaling its broad pipeline of products to commercial ...
(Date:12/11/2009)... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... the appointment of Dr. Alan Warrander to the ... Business Development. ,, "Dr. Warrander will be responsible ... for REOLYSIN(R)," said Dr. Brad Thompson, President and ... the design of a Phase 3 trial examining ...
(Date:12/10/2009)... Corporation (Nasdaq: DNDN ) announced today that it ... of its common stock at a price to the ... to the underwriters a 30-day option to purchase up ... cover overallotments, if any. The offering is expected ... closing conditions. ,, J. P. Morgan Securities Inc. and ...
(Date:12/10/2009)... -- Endologix, Inc. (Nasdaq: ELGX ), developer ... today that Dan Lemaitre, former President and CEO ... Directors effective December 11, 2009. Endologix now ... ,, Franklin D. Brown, Chairman of the Board, ... to the Endologix Board of Directors. He ...
Breaking Biology Technology:Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3Endologix Appoints Dan Lemaitre to its Board of Directors 2
... HONG KONG, Feb. 18 /PRNewswire-Asia/ -- Obio ... business growth ticket to the,international pharmaceutical arena. ... backed up by strong international investors including ... Group, Tai Sang Land Properties,Limited, Yu Hwa ...
... PharmaNet Development Group, Inc. (the "Company") (Nasdaq: ... to innovative pharmaceutical, biotechnology, generic drug and medical device ... in Sao Paulo, Brazil to further enhance its Latin ... Latin America since 2002 with a network of field-based ...
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE ... months ended December 31, 2008. Net loss for the three ... per share, compared with a net loss of $1,049,838 or ... 31, 2007. This increase in net loss was primarily ...
Other Biology Technology:Obio Pharmaceutical Announces Product Growth Strategy 2Obio Pharmaceutical Announces Product Growth Strategy 3PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 2PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 3PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 4PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 5Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 4Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 5Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 6Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 7
(Date:12/11/2009)... wild apples that could be an ancestor of today,s ... Asia. A new study comparing the diversity of recently ... Armenia with previously collected varieties originating in Russia and ... collection that will make M. orientalis more ... identify and record the genetic diversity of these wild ...
(Date:12/11/2009)... stress collectively weigh and initiate different survival strategies say ... strategic decisions that affect their health, wealth and the ... this week in the early online edition of the ... , was accomplished when the scientists applied the mathematical ... of genes and proteins that colonies of bacteria rely ...
(Date:12/11/2009)... University has granted an 18-month, exclusive option to ... insulin analogs. The company must reach certain milestones ... an exclusive license on therapies designed to help ... developing treatments that it hopes will become an ... insulin market. Insulin is a therapeutic protein used ...
Breaking Biology News(10 mins):Understanding apples' ancestors 2Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Dee Snider Leads 2009 March of Dimes Bikers for Babies 28R 29 48644 1Dee Snider Leads 2009 March of Dimes Bikers for Babies 28R 29 48644 2Oncology Program at Texas Health Dallas Receives Outstanding Achievement Award 48641 1Oncology Program at Texas Health Dallas Receives Outstanding Achievement Award 48641 2Protein Branded As Culprit in Mad Cow Disease 48638 1Protein Branded As Culprit in Mad Cow Disease 48638 2
... of Medicine scientists in the Department of Physiology and Cell Biology ... chromosome that may have significant implications for male infertility and contraception. ... This important discovery has been published in Nature ... biomedical research based upon the impact factor. , ...
... levels of carbon dioxide in the atmosphere are a ... The lack of atmospheric carbon dioxide (CO 2 ) ... their aquatic relatives, microalgae. , For plants and microalgae, ... their photosynthesis process that, along with sunlight, manufactures sugars ...
... Max Perutz was a campaigner for humanitarian causes, essayist, and ... has just been released by Cold Spring Harbor Laboratory Press. ... letters in the book What a Time I am ... life through his own vivid, erudite, and humorous pen. , ...
Other Biology News:Small RNAs can play critical roles in male infertility/contraception 2ISU researcher identifies protein that concentrates carbon dioxide in algae 2Selected personal letters of Max Perutz are released in new book 2
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
... Glucagon-like peptide-1(7-36) amide (GLP-1), C-terminal reactive. ... shows <0.1% cross reactivity with the ... other related peptides such as hGLP-2, ... mammalian species. GLP-1 is identical in ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
Biology Products: